Skip to content
RVBA-AMGEN

Amgen — full event log

Every event we have on file across every reporting year. The Data-by-year tab summarises the top 10 per year; this page shows them all.

← back to Data by year

2024· 11 events

90% renewable electricity; on-site solar at new Ohio facilityData confidence — high

In 2024, Amgen sourced 90% renewable electricity across its facilities and achieved a 46% reduction in Scope 1+2 absolute carbon emissions (excluding offsets). The new Ohio fully-electric biomanufacturing facility includes an on-site solar array sized to generate 2,038 MWh annually and deliver renewable energy back to the local grid. Aim is for all Amgen facilities, wherever feasible, to procure 100% renewable energy by 2027.

sustainability_report p.15

Primary: Amgen Ecovation™ electrified biomanufacturingData confidence — high

New facilities in North Carolina and Ohio were built using the Amgen Ecovation™ approach — flexible modular designs that are faster, lower-cost, and require less energy and water than traditional plants. The Ohio plant is Amgen's first fully electric biomanufacturing site, supporting the 2027 Scope 1+2 carbon neutrality goal.

sustainability_report p.15

TNFD alignment and biodiversity gap analysisData confidence — high

Using initial gap analysis and ongoing alignment with TNFD framework to shape local mitigation and conservation strategies; identifying proximity of largest sites to biodiversity hotspots and legally protected areas.

sustainability_report p.14

High-quality Scope 1 carbon offsets augmenting efficiency portfolioData confidence — high

In 2024, Amgen began augmenting its energy efficiency project portfolio with high-quality Scope 1 carbon emission offsets to assist progress toward its 2027 carbon neutrality ambition. Scope 1 emissions in 2024 include 40,000 MT of high-quality carbon offsets. The report frames these as offsets rather than durable removals.

sustainability_report p.15

Dependent: SBTi Scope 3 supplier engagement (73% by spend)Data confidence — high

On track to reach 2027 SBTi Scope 3 supplier target of engaging 73% of suppliers by spend in key categories to support their adoption of science-based targets. Science-based goal setting has also been embedded in Amgen's sourcing criteria.

sustainability_report p.14

Primary: Water and waste reduction projectsData confidence — high

In 2024 Amgen executed 198,000 CM of water saving projects and over 300 MT of waste reduction projects. Through 2024, achieved 57% of the 2027 40% water reduction target and 66% of the 75% waste reduction target vs a 2019 baseline.

sustainability_report p.15

2027 carbon neutrality (Scope 1+2) and SBTi Scope 3 supplier engagement targetaffects net zero target yearData confidence — high

By 2027, achieve carbon neutrality for Amgen-owned and -operated facilities and operations; SBTi Scope 3 supplier engagement target to engage with 73% of suppliers by spend in key categories.

sustainability_report p.25

Carbon offsets included in Scope 1affects scope 1 co2eData confidence — high

In 2024, Scope 1 carbon emissions includes 40,000 MT of high-quality carbon offsets to assist progress toward carbon neutrality ambition.

sustainability_report p.15

TRUE Zero Waste Platinum at San Francisco R&DData confidence — high

Achieved platinum-level TRUE Zero Waste Certification at San Francisco R&D facility, diverting more than 105 MT of waste from incineration and landfill.

sustainability_report p.15

First fully electric biomanufacturing facility opened (Ohio)Data confidence — high

Opened first fully electric Amgen biomanufacturing site in Ohio with on-site solar array sized to generate 2,038 MWh annually.

sustainability_report p.15

Primary: Commercial fleet electrificationData confidence — high

Increased EV adoption to 687 vehicles across the US, EU, Japan, Australia and South Korea, on track toward a corporate-wide goal of 1,800 EVs by 2027 (30% of total fleet vs 2019 baseline). Field-based employees in the US, Japan and EU must select all-electric or hybrid vehicles. Fleet carbon emissions were 33% lower than the 2019 baseline in 2024.

sustainability_report p.14

2023· 2 events

Horizon Therapeutics acquisitionData confidence — high

The 2023 and 2024 data include the acquisition of Horizon Therapeutics plc on October 6, 2023. Increases scale, employees, and revenue base.

sustainability_report p.20

Restated motor vehicle CPMM methodologyData confidence — high

In 2023, Amgen restated its collisions per million miles (CPMM) data for 2021 and beyond to use business miles only; previous calculations included personal and business miles.

sustainability_report p.19